Veracyte (NASDAQ:VCYT) Issues Quarterly Earnings Results

Key Points

• Veracyte delivered a strong Q1, reporting $139.1M in revenue (up 21% YoY), adjusted EBITDA of $42.8M (30.8% margin) and raised 2026 revenue guidance to $582M–$592M with adjusted EBITDA >26%.
• The Decipher franchise is the primary growth driver (~28,000 tests, +24% YoY) while Afirma volumes improved to ~17,200 (+12%) after a V2 transcriptome transition that cut no‑result rates and boosted margins.
• Veracyte has a strong liquidity position ($439.1M in cash/short‑term investments and $35.2M cash from operations) and two near‑term potential catalysts—Prosigna LDT and TruMRD—though commercial impact depends on trial readouts, guidelines and reimbursement.

Veracyte (NASDAQ:VCYT - Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.03, Zacks reports. Veracyte had a return on equity of 8.05% and a net margin of 12.83%.

Here are the key takeaways from Veracyte's conference call:

• Veracyte delivered a strong Q1 with $139.1M total revenue (up 21% YoY), testing revenue of $135.1M (+26%), adjusted EBITDA of $42.8M (30.8% margin), and raised 2026 revenue guidance to $582M–$592M with adjusted EBITDA >26%.
• The Decipher franchise remains the primary growth engine—~28,000 tests in Q1 (+24% YoY), ~30% growth in high‑risk categories, and multiple Phase III studies (GUIDANCE, ENZAMET, PredictRT) and NCCN inclusion supporting longer‑term uptake.
• Afirma volumes improved to ~17,200 tests (+12% YoY) after the full transition to the V2 transcriptome, which materially reduced no‑result rates (adding ~400 bps to volume) and contributed to margin improvement.
• Two upcoming launches—Prosigna LDT (OPTIMA data at ASCO; commercial mid‑year) and TruMRD in muscle‑invasive bladder cancer (launch by end of Q2)—are positioned as major catalysts, but commercial impact is contingent on trial readouts, guideline/reimbursement decisions and adoption.
• Strong cash generation ($35.2M from operations; $439.1M cash/short‑term investments) and improved gross margins (non‑GAAP 75.7%) provide flexibility to fund R&D, commercial scale-up and selective M&A aligned with the company’s oncology focus.

Veracyte Stock Down 1.4%

Shares of VCYT stock traded down $0.48 on Tuesday, reaching $32.97. The company had a trading volume of 1,493,042 shares, compared to its average volume of 871,886. The business's 50-day moving average is $33.38 and its 200 day moving average is $38.17. Veracyte has a one year low of $22.61 and a one year high of $50.71. The stock has a market capitalization of $2.63 billion, a PE ratio of 39.72 and a beta of 1.89.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on VCYT shares. UBS Group reiterated a "buy" rating on shares of Veracyte in a research report on Monday, January 12th. Guggenheim lowered their price objective on Veracyte from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Monday, March 30th. Needham & Company LLC restated a "buy" rating and issued a $48.00 price target on shares of Veracyte in a research report on Wednesday, April 1st. Morgan Stanley decreased their price target on Veracyte from $48.00 to $37.00 and set an "underweight" rating on the stock in a research report on Thursday, March 5th. Finally, Jefferies Financial Group started coverage on Veracyte in a research report on Monday, April 13th. They issued a "buy" rating and a $45.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $43.83.

Insider Activity at Veracyte

In other news, SVP Annie Mcguire sold 6,658 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $35.55, for a total value of $236,691.90. Following the sale, the senior vice president directly owned 94,706 shares in the company, valued at approximately $3,366,798.30. This trade represents a 6.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc Stapley sold 45,523 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $35.97, for a total transaction of $1,637,462.31. Following the completion of the sale, the chief executive officer owned 357,554 shares in the company, valued at approximately $12,861,217.38. The trade was a 11.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 75,782 shares of company stock valued at $2,722,097. 1.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Veracyte

Hedge funds have recently made changes to their positions in the stock. Empowered Funds LLC acquired a new stake in shares of Veracyte in the 4th quarter valued at approximately $42,000. Smartleaf Asset Management LLC boosted its stake in shares of Veracyte by 159.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 679 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Veracyte by 289.9% during the second quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 893 shares in the last quarter. State of Wyoming acquired a new stake in shares of Veracyte during the fourth quarter valued at about $81,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Veracyte during the fourth quarter valued at about $110,000.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte's proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company's flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.